Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-101 + Osimertinib in EGFR-mutated Metastatic NSCLC
NCT04743505Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by Washington University School of Medicine. Started Jan 2022; status: active, not recruiting.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04743505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04743505.